Drugs / DeTIL-0255
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05107739 | Dec 2021 → May 2023 | cervical cancer, endometrial cancer, refractory malignant neoplasm | Nurix Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | De-TIL-0255 | “A Study of DeTIL-0255 in Adults With Advanced Malignancies” NCT05107739 ↗1“Drug Product De-TIL-0255” NCT05107739 ↗ |
| Modality | Cell therapy | “Autologous tumor-infiltrating lymphocytes” NCT05107739 ↗ |